Prognostic significance of p53 immunostaining in epithelial ovarian cancer. - Archive ouverte HAL
Article Dans Une Revue Journal of Clinical Oncology Année : 1994

Prognostic significance of p53 immunostaining in epithelial ovarian cancer.

L. C. Hartmann
  • Fonction : Auteur
K. C. Podratz
  • Fonction : Auteur
G. L. Keeney
  • Fonction : Auteur
N. A. Kamel
  • Fonction : Auteur
J. H. Edmonson
  • Fonction : Auteur
J. Q. Su
  • Fonction : Auteur
J. A. Katzmann
  • Fonction : Auteur
P. C. Roche
  • Fonction : Auteur

Résumé

PURPOSE: To evaluate the prognostic significance of p53 expression in epithelial ovarian cancer, including a subset of stage I patients, and to look for correlations between p53 expression and other disease parameters, including stage, grade, age, histologic subtype, second-look results, ploidy, and percent S phase. PATIENTS AND METHODS: We analyzed p53 expression in 284 patients with epithelial ovarian cancer using immunohistochemical techniques in paraffin-embedded specimens. There were 36 patients with stage I disease, 20 with stage II disease, 186 with stage III disease, and 42 with stage IV disease. RESULTS: p53 immunoreactivity was present in 177 cases (62%). p53 expression was associated with grade 3 to 4 disease (P = .003). The following factors were associated with a decrease in overall survival in a univarate analysis: stage III or IV disease (P = .0001), grade 3 or 4 disease (P = .0001), age above the median (P = .0002), and p53 reactivity (P = .04). In a multivariate analysis, stage, grade, and age retained independent prognostic significance. In the subset of 36 stage I patients, p53 positively approached statistical significance (P = .10) as a negative prognostic factor in a univariate analysis. CONCLUSION: Abnormalities of p53 expression occur commonly in epithelial ovarian cancer. Although associated with decreased survival in a univariate analysis, this biologic marker did not retain independent prognostic significance in a multivariate analysis. p53 expression should be studied in a larger cohort of early-stage patients, where accurate prognostic information is needed to direct therapy.

Domaines

Chimie organique
Fichier non déposé

Dates et versions

hal-00815315 , version 1 (18-04-2013)

Identifiants

  • HAL Id : hal-00815315 , version 1
  • PUBMED : 8270986

Citer

L. C. Hartmann, K. C. Podratz, G. L. Keeney, N. A. Kamel, J. H. Edmonson, et al.. Prognostic significance of p53 immunostaining in epithelial ovarian cancer.. Journal of Clinical Oncology, 1994, 12 (1), pp.64-9. ⟨hal-00815315⟩
30 Consultations
0 Téléchargements

Altmetric

Partager

More